Blood pressure (BP) is usually recorded at every visit to the physician, yet patterns of BP over time in populations are not often published. BP trajectories have been reported in longitudinal studies of children ([@B1],[@B2]), but trajectories in adults with diabetes are usually ancillary to treatment trials for hypertension, and the results are explained in terms of the assigned medication ([@B3],[@B4]). In healthy adults evaluated longitudinally, systolic BP is relatively stable until approximately age 50, after which there is a steady increase with age ([@B5]). Diastolic BP increases longitudinally with age in healthy adult men, but in women, it increases in middle age and declines slightly after age 70 ([@B5]). In the Framingham population, systolic BP increased from age 30 through 84 but diastolic BP increased in middle age (40--60 years) and then declined afterward ([@B6]). This follows a similar pattern to that reported with cross-sectional data from the National Health and Nutrition Examination Study ([@B7],[@B8]). In the Göteberg population, systolic BP increased until age 75 and decreased between 75 and 79 in those without antihypertensive therapy, whereas diastolic BP increased during middle age and then decreased after age 75 ([@B9]).

Missing from the medical literature are longitudinal BP trajectories in populations with diabetes. In particular, BP trajectories before death have yet to be reported. Therefore, we investigated patterns of BP over time in a longitudinal study of Medicare patients within a diabetes registry.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Type of study {#s6}
-------------

We conducted a nonconcurrent longitudinal study using secondary data analysis of electronic medical record information linked to Medicare claims.

Study population {#s7}
----------------

We studied 3,766 Medicare beneficiaries with diabetes, attributed by the Centers for Medicare & Medicaid Services (CMS) to the University of Michigan Faculty Group Practice based on their participation in the Physician Group Practice Demonstration ([@B10]), who were entered into the University of Michigan diabetes registry from 2005 through 2008. Patients in the diabetes registry are adults (aged ≥18 years) who have met the following three criteria:have a diagnosis of diabetes in the Problem Summary List or a diagnosis of diabetes in the past 3 years with at least two face-to-face encounters in an ambulatory care setting or one face-to-face encounter in an acute care setting such as the emergency department;have received antihyperglycemic medication, diabetic supplies (strips/lancets/glucometer), have a HbA~1c~ \>6.4% or two or more glucose results ≥200 mg/dL; andwere seen by a primary care physician, geriatric, or an endocrinology specialist at least twice in the past 2 years, with one of those visits in the past 395 days.

Data {#s8}
----

CMS provided complete claims data each year for the beneficiaries assigned to the Physician Group Practice Demonstration project. National Claims History files contained information on beneficiary diagnoses, utilization of services, and Medicare payments made to providers for these services. Medicare enrollment data included age, sex, and geographic information.

The diabetes registry is a central repository for clinical data from various systems related to disease management and preventive care services. During the study period, registry information was updated between every day and monthly (varying by data element), and patient-centered summary reports were produced every 6 months. Eight reporting cycles occurred from 2005 through 2008, two for each of the 4 years. Accordingly, patients in the study may have had as many as eight BP reports. To study trends longitudinally, patients must have had at least two reports to be included in this study cohort.

Variables and their measurement {#s9}
-------------------------------

Data used for this analysis included age, sex, race, Medicaid insurance, height and weight, medications (statins, insulin, ACE inhibitors, angiotensin receptor blockers \[ARB\]), and the most recent HbA~1c~ and LDL cholesterol levels. BMI was calculated from height and weight. Death was determined from the Medicare enrollment file and the medical records. Comorbidities were obtained from Medicare claims, and included specific diseases as well as the annual Medicare assignment of Hierarchical Condition Categories (HCCs), which were used to derive the overall burden of disease (i.e., severity scores) ([@B11]). Individual comorbid conditions included congestive heart failure (CHF), renal failure or dialysis, severe malignancies (digestive tract, lung, and other severe cancers; acute leukemia; metastatic cancer), liver disease (end-stage liver disease, cirrhosis of the liver, or chronic hepatitis), and stroke (cerebral hemorrhage, ischemic or unspecified stroke, or hemiplegia/hemiparesis).

The BP measurements included in this study were the last BP recorded within each of the 6-month reporting periods. BP measurements during hospitalization or emergency department visits were excluded. For each patient, BP was determined by usual clinical practice during the outpatient office visit. Therefore, the procedure for measuring BP was similar to that used for clinical decision making at the point of care and was based on individual clinic processes and the judgment of the providers.

Analytic strategy {#s10}
-----------------

The participants represented a fluid cohort because various patients entered and/or left the study at various calendar times during the 4-year period. BP was recorded in 1,195 of the 3,766 subjects (32%) at each 6-month period during the course of the entire 4-year study (i.e., eight recorded BPs); BP was recorded at two periods for 410 (11%), with the remaining subjects observed for three to seven periods. To ensure that we were comparing a similar period before death for the patients who died, the BPs recorded before death were aligned (i.e., right-justified); thus, BP trajectories reflected the series of last BPs recorded before death. The main results are presented as right-justified for all patients, and sensitivity analyses were conducted using left-justification (i.e., BPs recorded as the patients entered the cohort).

Multilevel mixed-effects linear regression was the principal method of analysis. The likelihood ratio test for nested models was used to assess the significance of random intercepts and random coefficients (i.e., slopes). Trajectories were calculated using the fixed-portion linear predictor plus the contribution determined by the predicted random effects. An interaction term was used to evaluate significant differences in slopes between different subgroups. Age of the patient at the time of the report, ACE inhibitors or ARB drugs, statins, insulin, values of HbA~1c~ and LDL cholesterol, BMI, and disease severity score (HCC) were treated as time-varying covariates in the final regression models. The α was set at 0.05 (two-tailed).

Some data were missing on various 6-month reports for HbA~1c~ (5%), LDL cholesterol (16%), HCC score (22%), BMI (23%), and insulin (35%) during the course of the 4-year study. Because this was a large group, we chose not to impute values. Rather, we conducted a sensitivity analysis that included these additional variables in a fully adjusted regression model.

This study was approved by the University of Michigan IRB and conducted under a Data Use Agreement with CMS.

RESULTS {#s11}
=======

In this cohort, 32% of patients were aged \<65 and 30% were ≥75 years at the time of the initial visit ([Table 1](#T1){ref-type="table"}). Women accounted for 54% of subjects, and 80% of the patients were white. At the time of entry into the study, 68% of patients were receiving ACE/ARB therapy, and 66% were receiving statin medications. There were 404 patients (10.7%) who died, half of whom were aged ≥75 years at the initial visit. Increasing age and male sex were risk factors for death, whereas statin therapy was protective. CHF, dialysis or renal failure, stroke, liver disease, and malignancy were significant predictors of death.

###### 

Characteristics of patients with diabetes at baseline and mortality during the study period

  Variables                                   All subjects   Mortality    *P*
  ------------------------------------------- -------------- ------------ ---------
  Age (years)                                                             
   \<65                                       1,215 (32.3)   96 (7.9)     
   65--69                                     745 (19.8)     48 (6.4)     
   70--74                                     679 (18.0)     57 (8.4)     
   \>75                                       1,127 (29.9)   203 (18.0)   \<0.001
  Sex                                                                     
   Male                                       1,747 (46.4)   212 (12.1)   
   Female                                     2,019 (53.6)   192 (9.5)    0.009
  Race                                                                    
   White                                      3,026 (80.4)   335 (11.1)   
   African American                           482 (12.8)     47 (9.8)     
   Other                                      258 (6.8)      22 (8.5)     0.340
  Payer                                                                   
   Medicaid[\*](#t1n1){ref-type="table-fn"}   714 (19.0)     79 (11.1)    
   Other                                      3,052 (81.0)   325 (10.6)   0.747
  ACE/ARB therapy                                                         
   Yes                                        2,572 (68.3)   264 (10.3)   
   No                                         1,194 (31.7)   140 (11.7)   0.178
  Statin therapy                                                          
   Yes                                        2,473 (65.7)   241 (9.7)    
   No                                         1,293 (34.3)   163 (12.6)   0.007
  CHF                                                                     
   Yes                                        753 (20.0)     179 (23.8)   
   No                                         3,013 (80.0)   225 (7.5)    \<0.001
  Dialysis or renal failure                                               
   Yes                                        639 (17.0)     169 (26.4)   
   No                                         3,127 (83.0)   235 (7.5)    \<0.001
  Stroke or hemiplegia                                                    
   Yes                                        246 (6.5)      53 (21.5)    
   No                                         3,520 (93.5)   351 (10.0)   \<0.001
  Liver disease                                                           
   Yes                                        73 (1.9)       23 (31.5)    
   No                                         3,693 (98.1)   381 (10.3)   \<0.001
  Metastatic cancer                                                       
   Yes                                        117 (3.1)      39 (33.3)    
   No                                         3,649 (96.9)   365 (10.0)   \<0.001

Data are presented as *n* (%).

\*Medicaid dually eligible and Medicaid only.

Systolic and diastolic BP both significantly declined before death in patients with diabetes. In an unadjusted model, mean systolic BP declined 3.1 mmHg (95% CI 1.9--4.3) and mean diastolic BP declined 1.6 mmHg (0.9--2.3) annually before death. In the adjusted model ([Table 2](#T2){ref-type="table"}), systolic pressure decreased by 3.2 mmHg/year (*P* \< 0.001) in those who died and by 0.7 mmHg/year (*P* \< 0.001) in those who did not die (*P* \< 0.001 for the difference in slopes between trajectories). Diastolic pressure declined by 1.3 mmHg/year for those who died (*P* \< 0.001) and by 0.6 mmHg/year for those who did not die (*P* \< 0.001); the difference in slopes remained significant (*P* = 0.021). The addition of a quadratic term to detect a nonlinear change in slope was not significant for systolic (*P* = 0.965) or diastolic BP (*P* = 0.761) in the adjusted models. BP trajectories generated from the adjusted models are shown in [Fig. 1](#F1){ref-type="fig"} and [Fig. 2](#F2){ref-type="fig"}, with stratification by mortality.

###### 

Annual mean change in BP in patients with diabetes, by mortality

  Group                                                  Patients *n*   Annual change in BP (mmHg)   95% CI          *P* interaction
  ------------------------------------------------------ -------------- ---------------------------- --------------- -----------------
  Systolic BP                                                                                                        
   Adjusted model:[\*](#t2n1){ref-type="table-fn"}                                                                   
    Alive                                                3,362          −0.7                         −0.4 to −0.9    
    Died                                                 404            −3.2                         −2.2 to −4.2    \<0.001
   Fully adjusted model[†](#t2n2){ref-type="table-fn"}                                                               
    Alive                                                2,251          −0.5                         −0.02 to −1.1   
    Died                                                 169            −6.2                         −3.0 to −9.4    0.001
  Diastolic BP                                                                                                       
   Adjusted model[\*](#t2n1){ref-type="table-fn"}                                                                    
    Alive                                                3,362          −0.6                         −0.5 to −0.7    
    Died                                                 404            −1.3                         −0.7 to −1.9    0.021
   Fully adjusted model[†](#t2n2){ref-type="table-fn"}                                                               
    Alive                                                2,251          −0.4                         −0.05 to −0.7   
    Died                                                 169            −3.4                         −1.5 to −5.3    0.002

\*Adjusted for age, sex, race, Medicaid, ACE inhibitors or ARBs, statins, congestive heart failure, dialysis or renal failure, malignancies, liver disease, and stroke.

†Adjusted for age, sex, race, Medicaid, ACE inhibitors or ARBs, statins, congestive heart failure, dialysis or renal failure, malignancies, liver disease, stroke, BMI, HbA~1c~, LDL cholesterol, insulin, and disease severity score (HCC).

![Mean systolic and diastolic BP trajectories for patients with diabetes mellitus, by age and mortality.](1534fig1){#F1}

![Mean systolic and diastolic BP trajectories for patients with diabetes mellitus, by sex and mortality.](1534fig2){#F2}

In the fully adjusted model, mean systolic BP significantly increased with age (0.23 mmHg for each year; *P* \< 0.001), female sex (1.57 mmHg; *P* = 0.004), African American race (3.14 mmHg; *P* \< 0.001), BMI (0.11 mmHg for each kg/m^2^ increase; *P* = 0.001), and for those with renal failure or receiving dialysis (5.08 mmHg; *P* \< 0.001). Mean systolic BP significantly decreased with Medicaid insurance (−2.05 mmHg; *P* = 0.006) and in those with CHF (−4.03 mmHg; *P* \< 0.001). Mean diastolic BP significantly increased with African American race (2.58 mmHg; *P* \< 0.001) and BMI (0.07 mmHg; *P* = 0.001). Mean diastolic BP significantly decreased with age (−0.19 mmHg; *P* \< 0.001), female sex (−1.09 mmHg; *P* = 0.001), and in those with CHF (−1.27 mmHg; *P* = 0.003). Some of these findings are illustrated in [Fig. 1](#F1){ref-type="fig"} and [Fig. 2](#F2){ref-type="fig"}; the increased systolic BP with older age can be seen by the shift in the BP trajectories on the *y*-axis. Systolic BP is greater in older patients, whereas diastolic BP is lower in older patients. Women have higher systolic but lower diastolic BP than men.

In secondary analyses, the addition of HbA~1c~, LDL cholesterol, BMI, insulin, and severity risk score did not substantially change the major findings ([Table 2](#T2){ref-type="table"}, fully adjusted model). The decline in systolic BP was particularly evident (−6.2 mmHg/year) in those who died. We also evaluated potential differences in the slope of BP trajectories for those with and without CHF (regardless of mortality); the interaction term was not significant for systolic BP (*P* = 0.951) or diastolic BP (*P* = 0.056). Similarly, there was no effect modification by younger age (\<65 years) versus older age (≥65 years); the interaction terms for differences in slope were not significant for systolic (*P* = 0.184) or diastolic BP (*P* = 0.979).

We repeated the statistical analyses using left-justification of the BP measurements; the results did not appreciably change. The rate of decline of BP was greater in those patients who died than in patients who remained alive (*P* \< 0.001 for systolic BP; *P* = 0.013 for diastolic BP). Systolic BP decreased by 2.7 mmHg/year (95% CI 1.7--3.7) and diastolic BP decreased by 1.5 mmHg/year (95% CI 0.9--2.1) in those who died. Systolic BP declined by 0.7 mmHg/year (95% CI 0.5--0.9) and diastolic BP declined by 0.7 (95% CI 0.6--0.9) in the patients who remained alive.

Of the 404 patients who died, 62 (15%) died between the last clinic visit and the end of the reporting period, 86 (21%) died within 8 weeks of the last reporting period, 158 (39%) died within 8 to 24 weeks of the last reporting period, and 98 (24%) died \>24 weeks from the last reporting period.

CONCLUSIONS {#s12}
===========

Mean systolic and diastolic BP both declined in the years before death in patients with diabetes. This annual rate of decline was significantly more marked (−3.2 mmHg systolic and −1.3 mmHg diastolic) than in the patients who remained alive. Moreover, the decline was evident after adjustment for major organ failure---heart, kidney, and liver---as well as for common causes of death such as malignancies and stroke. These findings may signal an underlying population of vulnerable patients, although it is unclear whether the BP decline is merely a symptom of this vulnerability or is one of several physiologic contributors to the dying process.

The rate of change in BP has been of lesser significance than threshold values that serve as guides to initiation or adherence to antihypertensive therapy ([@B12]). Studies of outcomes in those who experience significant changes (either increases or decreases) in BP would be appropriate. Although hypertension in middle age is a risk factor for death, it is not clear whether there is a point at which therapy should be re-evaluated in the very old or in those with a marked rate of BP decline. A similar phenomenon has been found in cohorts evaluated for the incidence of dementia: elevated BP in earlier life increases the risk, but a decline in BP is evident in the 5 years just before diagnosis ([@B13]).

There are few studies that plot the trajectories of BP in patients with diabetes. Maddox et al. ([@B14]) plotted BP trajectories over time in patients with diabetes and/or chronic kidney disease who were newly diagnosed with coronary artery disease. Their results indicated that good control of BP decreased the risk of myocardial infarction and the risk of revascularization, although overall mortality did not improve.

There is some corroborating evidence for our findings. Analysis of a cohort monitored for a median of 9.8 years showed the risk of death in patients with type 2 diabetes increased by 15% for every 10-mmHg decrease in systolic BP and increased by 22% for every 10-mmHg decrease in diastolic BP ([@B15]). This inverse relationship was particularly evident in the oldest age group. Similarly, Rönnback et al. ([@B16]) reported that low systolic and diastolic BP predicted elevated all-cause and cardiovascular deaths in patients with type 2 diabetes during a median follow-up of 9.5 years.

The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial demonstrated that intensive hypertensive therapy did not reduce mortality in patients with type 2 diabetes; the hazard ratio for intensive versus standard BP therapy was 1.07 (95% CI 0.85--1.35) for all-cause mortality ([@B3]). Likewise, Cooper-DeHoff et al. ([@B17]) found that tight control of systolic BP in patients with diabetes and coronary artery disease did not improve mortality. The hazard ratio for all-cause mortality was 1.20 (95% CI 0.99--1.45); again, suggesting a nonsignificant excess of deaths in patients with tight BP control compared with those receiving usual care. They also showed that systolic BP of \<110 mmHg was associated with an increase in all-cause mortality compared with systolic BP of 125 to 130 mmHg.

The UK Prospective Diabetes Study Group found that tight BP control reduced diabetes-related deaths by 32% without a significant reduction in all-cause mortality after a median follow-up of 8.4 years ([@B18]). However, the Appropriate Blood Pressure Control in Diabetes (ABCD) trial demonstrated a decrease in all-cause mortality (*P* = 0.037) for intensive versus moderate BP therapy in patients with type 2 diabetes during a period of 5.3 years, despite showing no statistically significant differences in myocardial infarction, cerebrovascular, or congestive heart failure events ([@B19]).

Previous authors have noted a concern regarding aggressive treatment in older patients ([@B20],[@B21]). A meta-analysis of randomized controlled trials showed treatment of hypertension did not yield a significant reduction in all-cause mortality in patients aged ≥80 years ([@B20]). Moreover, a nonsignificant relative excess of all-cause death was noted in those who received antihypertensive treatment. However, only 14% of the participants had a history of diabetes. Bulpitt et al. ([@B21]) reported similar findings in an open pilot trial of patients aged ≥80 years, although the proportion with diabetes was not stated. In contrast, antihypertensive treatment in mostly nondiabetic individuals aged ≥80 years aimed to a BP target of 150/80 mmHg significantly reduced the rate of death from any cause by 21% ([@B22]).

Our investigation did not determine the reason for the declining BP before death, and therefore, we advise caution in the interpretation. We have little evidence to indicate whether treatment intensification played a role or whether declining BP is a harbinger of the dying process in certain patients. Our results suggest that the decrease in BP is not merely due to the presence of CHF or increased age. It is important to recognize that the decline was observed in the mean pressures in a population and was not observed in all individuals. Because this was a registry-based study, the findings should be investigated in a large, population-based cohort of patients with diabetes. It is unclear whether declining BP could be a reliable predictor of mortality or whether the patients in this registry differ from the overall population in ways that this investigation did not capture.

In conclusion, it may be useful to plot BPs over time in populations, similar to what many physicians do for individual patients with diabetes. The trajectory of BP leading up to death can be revealing. Our results suggest that a significant decline occurs in both systolic and diastolic BP several years before death in populations of patients with diabetes.
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